Study Title: Phase II, Randomized, Double-blind, Multi-centered Study of Polyphenon E in Men with High-grade Prostatic Intraepithelial Neoplasia (HGPIN)

What is Polyphenon E? 
 Polyphenon E is a highly purified tea catechin extract, made from 100% green tea leaves.  The catechins are extracted with hot water and spray-dried into a fine powder.  It is the first pharmaceutical grade green tea catechin in the world.  This study utilizes a decaffeinated variety.

Trial Details
Study Description: This multi-center trial will examine the safety and effectiveness of Polyphenon E in preventing Prostate Cancer in Men diagnosed with High-grade Prostatic Intraepithelial Neoplasia (HGPIN). 
Study Design:   Phase II, Randomized, Double-blind, Multi-centered Study 
 Primary Outcome Measures: Safety and Efficacy
Estimated Enrollment:   272
Study Start Date:   January 2008
Estimated Study Completion Date:   January 2013
Study Arms  
Subjects participating in the study will be randomized to receive either Polyphenon E (200 mg EGCG bid) or placebo (n=136/arm). All subjects will also be provided with a daily multivitamin/mineral supplement to ensure equivalent intake of essential nutrients. Study drug administration will continue from the time of randomization until the time of repeat biopsy; the planned/maximum duration of treatment is one year.
 
Major Inclusion Criteria:

Major Exclusion Criteria:

For the most up-to-date information, including study locations, go to:
http://www.clinicaltrials.gov/ct2/show/NCT00596011?term=high+grade+pin&rank=2